A pancreatic cancer therapy that utilizes injections of antibodies can double the survival rate of patients and represents a breakthrough in treating the disease, researchers announced yesterday in Taipei.
Lee Wen-hwa (李文華), chancellor of the China Medical University in Taichung and an Academia Sinica research fellow, told a news conference in Taipei that his team discovered that the cancer cells trigger the over-expression of the IL17RB receptor, a protein in the plasma membrane of surface pancreatic cancer cells that receives chemical signals.
The phenomenon is also seen in breast cancer cells, and his team had success in using the antibody to treat breast cancer.
“From our previous research, we knew that the over-expression of the IL17RB receptor positively correlates with conditions or breast cancer — the higher the level of over-expression, the worse the breast cancer becomes,” Lee said.
Hoping to replicate the success they had in treating breast cancer, the research team used the antibody targeting IL17RB on mice whose pancreases had been implanted with cancer cells and found that the survival rate of the mice doubled, from an average of 60 days to 120 days.
The antibody severs the intercellular pathway between IL17RB and chemokine, a protein secreted by cells that plays a key role in metastasis, thereby curbing the transfer of cancer cells, Lee said.
“When we cut the mice open, their lungs and livers were completely free from pancreatic cancer cells, indicating that the metastasis had been suppressed,” he said.
In addition, since IL17RB plays an insignificant role in other parts of the human body, targeting this receptor with an antibody causes minimal side effects, he said.
The findings also provide hope of treating other types of cancer that cause the over-expression of IL17RB, such as bladder cancer, oral cancer and some brain tumors, Lee said.
Pancreatic cancer is the 13th- most common cancer in the nation and is usually considered incurable, he said.
Because pancreatic cancer cells can move to other organs, operating on patients is very difficult and existing chemotherapy treatments can only extend a patient’s life by three to six months, he said.
More than 70 percent of people with pancreatic cancer die less than one year after diagnosis and about 90 percent of them die within five years, he said.
Lee said the antibody must be moderated for use on humans, which will take one to two years, and it must undergo clinical trials.
“Once it passes the clinical tests, it will enter mass production. We hope that it will become available for clinical use in five years,” he said.
A provisional patent application for the antibody was filed last year and the assessment of the patent will begin in June, Lee said.
A paper on the team’s research findings was submitted to the Journal of Experimental Medicine in September last year and was published on Tuesday last week.
CHANGING LANDSCAPE: Many of the part-time programs for educators were no longer needed, as many teachers obtain a graduate degree before joining the workforce, experts said Taiwanese universities this year canceled 86 programs, Ministry of Education data showed, with educators attributing the closures to the nation’s low birthrate as well as shifting trends. Fifty-three of the shuttered programs were part-time postgraduate degree programs, about 62 percent of the total, the most in the past five years, the data showed. National Taiwan Normal University (NTNU) discontinued the most part-time master’s programs, at 16: chemistry, life science, earth science, physics, fine arts, music, special education, health promotion and health education, educational psychology and counseling, education, design, Chinese as a second language, library and information sciences, mechatronics engineering, history, physical education
DEADLOCK: As the commission is unable to forum a quorum to review license renewal applications, the channel operators are not at fault and can air past their license date The National Communications Commission (NCC) yesterday said that the Public Television Service (PTS) and 36 other television and radio broadcasters could continue airing, despite the commission’s inability to meet a quorum to review their license renewal applications. The licenses of PTS and the other channels are set to expire between this month and June. The National Communications Commission Organization Act (國家通訊傳播委員會組織法) stipulates that the commission must meet the mandated quorum of four to hold a valid meeting. The seven-member commission currently has only three commissioners. “We have informed the channel operators of the progress we have made in reviewing their license renewal applications, and
The High Prosecutors’ Office yesterday withdrew an appeal against the acquittal of a former bank manager 22 years after his death, marking Taiwan’s first instance of prosecutors rendering posthumous justice to a wrongfully convicted defendant. Chu Ching-en (諸慶恩) — formerly a manager at the Taipei branch of BNP Paribas — was in 1999 accused by Weng Mao-chung (翁茂鍾), then-president of Chia Her Industrial Co, of forging a request for a fixed deposit of US$10 million by I-Hwa Industrial Co, a subsidiary of Chia Her, which was used as collateral. Chu was ruled not guilty in the first trial, but was found guilty
Taiwan People’s Party (TPP) Chairman Huang Kuo-chang (黃國昌) yesterday appealed to the authorities to release former Taipei mayor Ko Wen-je (柯文哲) from pretrial detention amid conflicting reports about his health. The TPP at a news conference on Thursday said that Ko should be released to a hospital for treatment, adding that he has blood in his urine and had spells of pain and nausea followed by vomiting over the past three months. Hsieh Yen-yau (謝炎堯), a retired professor of internal medicine and Ko’s former teacher, said that Ko’s symptoms aligned with gallstones, kidney inflammation and potentially dangerous heart conditions. Ko, charged with
RSS